← Every applicant
Janssen Biotech FDA Approvals
10 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| ICOTYDENew drugMar 17, 2026TABLET, ORAL |
| RYBREVANT FASPRONew drugFeb 13, 2026VIAL, SINGLE-USE |
| RYBREVANT FASPRONew drugDec 17, 2025INJECTION |
| INLEXZONew drugSep 9, 2025SYSTEM, INTRAVESICAL |
| IMAAVYNew drugApr 29, 2025INJECTABLE, INJECTION |
| LAZCLUZENew drugAug 19, 2024TABLET, ORAL |
| AKEEGANew drugAug 11, 2023TABLET, ORAL |
| TALVEYNew drugAug 9, 2023INJECTABLE, INJECTION |
| TECVAYLINew drugOct 25, 2022INJECTABLE, INJECTION |
| RYBREVANTNew drugMay 21, 2021INJECTABLE, INJECTION |